ArticleESMO gastrointestinal oncology2026
Real-world outcomes and prognostic factors of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer: a multicenter study in Spain.
Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04737187 (An Open-label, Randomized, Phase III Study Comparing Trifluridine/Tipiracil in Combination With Bevacizumab to Trifluridine/Tipiracil Monotherapy in Patients With Refractory Metastatic Colorectal Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-label, Randomized, Phase III Study Comparing Trifluridine/Tipiracil in Combination With Bevacizumab to Trifluridine/Tipiracil Monotherapy in Patients With Refractory Metastatic Colorectal Cancer (SUNLIGHT Study)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Trifluridine/tipiracil plus bevacizumab (FTD/TPI+BEV) has demonstrated survival benefit in patients with metastatic colorectal cancer (mCRC) after failure of at least two prior treatment regimens in the phase III SUNLIGHT trial (NCT04737187), which compared FTD/TPI+BEV with FTD/TPI monotherapy; however, real-world evidence remains limited. The BeTAS real-world study evaluated the real-world effectiveness and safety of FTD/TPI+BEV in Spanish routine clinical practice. Patients and methods: This ambispective, multicenter observational study included 549 patients with mCRC treated with FTD/TPI+BEV across 19 Spanish university hospitals [retrospectively (2019-2023) and prospectively (from 2024 onward)]. Outcomes included overall survival (OS), progression-free survival (PFS), and tumor response according to RECIST version 1.1. Safety was assessed using Common Terminology Criteria for Adverse Events version 5.0. Univariate and multivariate analyses evaluated baseline and treatment-emergent prognostic factors. Results: Median OS was 10.8 months and median PFS was 5.0 months. The objective response rate was 9.6% and the disease control rate was 51.9%. Treatment efficacy was independent of sex, Conclusions: FTD/TPI+BEV is effective and well tolerated in Spanish real-world clinical practice, consistent with SUNLIGHT. Baseline prognostic classification, performance status, metastatic burden, and treatment-emergent factors were associated with clinical outcomes. The observed associations for grade 3-4 neutropenia and primary prophylactic G-CSF use should be considered exploratory and hypothesis-generating.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.